Triplet immunotherapy improves survival in HER2‑positive gastric cancer, suggesting broader immune activation
New data from a study of HER2‑positive gastric cancer patients evaluated a triplet immunotherapy regimen. The analysis compared the combination against standard approaches and focused on overall survival and response durability.
The results showed that the triplet therapy increased survival rates and produced more durable responses than the comparator treatments. These outcomes indicate a clear benefit for patients receiving the three‑drug combination.
The findings also hint that the therapy may stimulate the immune system beyond the HER2 target, opening possibilities for broader anti‑cancer activity.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question”
read at onclive ↗
comments(0)
5-min edit window · permanent after that